Comparative Pharmacology
Head-to-head clinical analysis: MINTEZOL versus VERMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MINTEZOL versus VERMOX.
MINTEZOL vs VERMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiabendazole inhibits the mitochondrial fumarate reductase system in susceptible helminths, disrupting energy metabolism.
Binds to β-tubulin in parasitic cells, inhibiting microtubule polymerization, thereby impairing glucose uptake and causing energy depletion and parasite death.
50 mg/kg/day orally in 2-3 divided doses, maximum 3 g/day, for 2-3 days.
Mebendazole 100 mg orally twice daily for 3 days for pinworm, whipworm, hookworm, and roundworm infections. For pinworm, may repeat after 2 weeks. For hookworm and whipworm, may require longer courses.
None Documented
None Documented
Terminal elimination half-life: 2-8 hours (mean 4 hours). Hepatic impairment prolongs; dose adjustment recommended.
2-8 hours (terminal half-life, may be prolonged in hepatic impairment or obstruction)
Renal: 90% within 24 hours (5% unchanged, 85% as metabolites). Fecal: <10%.
Fecal (90%) as unchanged drug and metabolites; renal (<10%)
Category C
Category C
Anthelmintic
Anthelmintic